section name header

Evidence summaries

Nortriptyline and Gabapentin, Alone and in Combination for Neuropathic Pain

Combined gabapentin and nortriptyline may be more efficacious than either drug given alone for neuropathic pain. Level of evidence: "C"

A trial1 included a total of 56 subjects with diabetic polyneuropathy or postherpetic neuralgia. They received daily oral gabapentin, nortriptyline, and their combination. In sequence, a different drug was given to each randomised group in 3 treatment periods. During each 6-week treatment period, drug doses were titrated towards maximum tolerated dose. Mean daily pain (0—10) was 5.4 (95% CI 5.0 to 5.8) at baseline, and at maximum tolerated dose, pain was 3.2 (2.5 to 3.8) for gabapentin, 2.9 (2.4 to 3.4) for nortriptyline, and 2.3 (1.8 to 2.8) for combination treatment. Pain with combination treatment was significantly lower than with gabapentin (0.9, 95% CI 1.4 to 0.3) or nortriptyline alone (0.6, 95% CI 1.1 to 0.1). At maximum tolerated dose, the most common adverse event was dry mouth, which was significantly less frequent in patients on gabapentin than on nortriptyline or combination treatment.

Comment: The quality of evidence is downgraded by imprecise results (one small trial).

    References

    • Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009 Oct 10;374(9697):1252-61. [PubMed]

Primary/Secondary Keywords